Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Ricky - ah yes, apols. Still, ~£18k tied up here when he could put it literally anywhere else - the choice is his - seems weird when he is so ultra critical of everything to do with ORPH and CF. He must think the risk-reward is worth it.
I think you kindly told us the other day that you have sold around 300k ORPH shares and still hold around 600k. Do you think there is any investment anywhere in the world, any sector that is going to deliver better returns than ORPH at the moment? If you do then should you not sell your 600k shares and put the money into that? If you're keeping your 600k that presumably means you recognise the excellent prospects here. What is your target price?
The NYT article isn't written to provide new info to people who are already well versed with with ORPH does. That's what RNSs do. It's to raise awareness with a much much wider group so far uninitiated, which I would say is a very good thing, wouldn't you?
Mo Khan, Incoming Non-Executive Director, Open Orphan, said: "I am delighted to join the Board of Open Orphan. I have been very impressed by the outstanding progress that Cathal Friel, the Board and the team have made in such a short period of time. These are exciting times for Open Orphan and its subsidiaries in the light of their current full-service, high quality offerings in conjunction with the increased interest in challenge studies. I look forward to working with them in the next stage of the evolution of Open Orphan."
Looks like a good appointment. This from Pharm-Olam web site: Dr. Yamin "Mo" Khan joined Pharm-Olam in May 2000 and has worked in the company across various departments including clinical operations, project management, business development and executive management. Dr. Khan currently holds the post of executive vice president of global clinical development and is responsible for business development, strategic partnerships and executive oversight.
DS - precisely = mission accomplished for the de-rampers. We need to keep it coming in spite of them.
He didn't need to say it though. Shouldn't rule anything out at this stage. Covid still a huge driver for wider pharma industry. Brain in gear before mouth please CF.
Well done Si, you can't be too careful with these things.
c0ck
Ndn - did you spot anything positive today that you feel worth commenting on? You are an investor after all.
Ndn - you still here desperately picking holes? What's wrong with you?
AB - please don't blame the NHS. The perpetual structural change and associated costs is driven by the Department if Health - part of government. I can tell you the NHS would like a few years of no organisational change when we can be allowed to focus entirely on what we are here for and want to do - provide the best possible health care.
Well at least it was brief
FO earache. Stop filling this bb up with your relentless, tedious, verbose crap. No-one's interested.
just for clarity, it wouldn't be the NHS being slow, and I imagine NHS oncologists and their colleagues in cancer treatment who are aware will be very keen to get their hands on parsortix. However new products etc have to be approved by the MHRA which is part of the Department of Health which is an executive branch of the government. So any sluggishness would more likely be down to the influence govt have over MHRA. In the covid space we have seen this has been very unhelpful to the UK diagnostics industry and consequently the wider population (with the MHRA ignoring / delaying high quality, UK-developed tests whilst monstrous deals with inferior chinese offerings have inexplicably been put in place), despite weazle words from the PM and others.
Angle need a champion high up in the DH. Someone should take Chris Whitty out for lunch.
I'm sure its us ..
https://www.clinicaltrials.gov/ct2/show/NCT04752644
they are complete and utter bastards. only in it for what benefits they can get personally, irrespective of the damage being done to society. They know they won't be here after next election, and are just bank-rolling all their dodgy deals for as long as they can until the carpet is pulled out from under them. ****s. All IMHO.
... oh yes, and ... "for those who wait, I think they'll be rewarded" !!
I'm waiting, well invested (for a relatively impoverished ex NHS worker!), and looking forward to a great couple of years ..
that interview yesterday was just SO good. Couple of take-outs for me:
"We'll see quite a lot more [of CF] in the weeks and months ahead" ... the market likes newsflow ...
"We're in one of the greatest 'gold rushes' ever ... the infectious disease market is expanding 10-fold in the next 4 years ... we're there to test many of the products ..."
So much else in that brief interview that could be highlighted. All good! Here's a link if you haven't seen it yet ...
https://www.brrmedia.co.uk/broadcasts-embed/6123b6a60e6e7c49dbb1e2f0/?popup=true
GLA investors.
thanks Herne (and Eskers of course ... how does he find this stuff?) Here's an extract:
"We look forward to reporting the Phase 2 results for ABNCoV2, as well as additional pivotal results from the RSV human challenge trial later this year."
"RSV - As planned, Bavarian Nordic initiated a Phase 2 human challenge trial of its RSV vaccine candidate, MVA-BN RSV in the first quarter of 2021. All subjects have been vaccinated and challenged, and the trial will generate the first efficacy data against RSV during second half of 2021. In parallel, activities to support a regulatory Phase 3 trial in 2022 are ongoing, pending results from the human challenge trial."
Illustrates the kind of important work ("pivotal" to this particular client) which is progressing in the background.
Well done CF and hVIVO.
Mr Beann - I agree. Let's try and keep this place positive now. Focus on the company, the fantastic prospects and exciting journey we're on.